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Background: Interferon-gamma release assays (IGRA) are well-established
immunodiagnostic tests for tuberculosis (TB) in adults. In children these tests are
associated with higher rates of false-negative and indeterminate results. Age is
presumed to be one factor influencing cytokine release and therefore test performance.
The aim of this study was to systematically review factors associated with indeterminate
IGRA results in pediatric patients.
Methods: Systematic literature review guided by the preferred reporting items for
systematic reviews and meta-analyses (PRISMA) searching PubMed, EMBASE, and
Web of Science. Studies reporting results of at least one commercially available IGRA
(QuantiFERON-TB, T-SPOT.TB) in pediatric patient groups were included. Random
effects meta-analysis was used to assess proportions of indeterminate IGRA results.
Heterogeneity was assessed using the I2 value. Risk differences were calculated for
studies comparing QuantiFERON-TB and T-SPOT.TB in the same study. Meta-regression
was used to further explore the influence of study level variables on heterogeneity.
Results: Of 1,293 articles screened, 133 studies were included in the final analysis.
These assessed QuantiFERON-TB only in 77.4% (103/133), QuantiFERON-TB and
T-SPOT.TB in 15.8% (21/133), and T-SPOT.TB only in 6.8% (9/133) resulting in
155 datasets including 107,418 participants. Overall 4% of IGRA results were
indeterminate, and T-SPOT.TB (0.03, 95% CI 0.02–0.05) and QuantiFERON-TB assays
(0.05, 95% CI 0.04–0.06) showed similar proportions of indeterminate results; pooled
risk difference was−0.01 (95% CI −0.03 to 0.00). Significant differences with lower
proportions of indeterminate assays with T-SPOT.TB compared to QuantiFERON-TB
Meier et al. Indeterminate IGRA Results in Children
were only seen in subgroup analyses of studies performed in Africa and in
non-HIV-infected immunocompromised patients. Meta-regression confirmed lower
proportions of indeterminate results for T-SPOT.TB compared to QuantiFERON-TB
only among studies that reported results from non-HIV-infected immunocompromised
patients (p < 0.001).
Conclusion: On average indeterminate IGRA results occur in 1 in 25 tests performed.
Overall, there was no difference in the proportion of indeterminate results between both
commercial assays. However, our findings suggest that in patients in Africa and/or
patients with immunocompromising conditions other than HIV infection the T-SPOT.TB
assay appears to produce fewer indeterminate results.
Keywords: Clinical studies, IGRA, latent, pediatrics, risk difference, QuantiFERON, T-SPOT.TB, T cell response
INTRODUCTION
Tuberculosis (TB) remains the leading cause of mortality by
a single infectious agent, accounting for an estimated 1.6
million deaths worldwide. According to the latest report by the
World Health Organization 10 million people are estimated to
have developed TB disease in 2017 (1). However, the majority
of individuals infected with Mycobacterium tuberculosis are
asymptomatic and remain in a latent stage of infection. Data
on infected individuals is not included in the World Health
Organization TB report as TB infection is not a notifiable
disease. Therefore, only estimates exist with one of the most
recent estimates suggesting that in 2014 a total of 1.7 billion
individuals, equivalent to 23% of the global population, had latent
TB infection (2).
Progression from latent TB infection to active TB disease
occurs in approximately one in ten adults. Children, however,
progress more frequently to active TB and progression may be
particularly rapid in the first 2 years of life (3–5). Early diagnosis
and treatment are therefore key to reduce the burden of active TB
in children.
Immuno-diagnostic tests are the main tools for the diagnosis
of latent TB infection and both the tuberculin skin test (TST)
and interferon-gamma release assays (IGRA) are used in the
clinical setting (6, 7). The latter have been developed to
overcome the limited specificity of the TST (8, 9). In adults
the two commercially available IGRA, the QuantiFERON-TB
and T-SPOT.TB—both existing in several test generations—have
replaced the TST in many settings, primarily in an attempt to
improve specificity (10).
In children, there is evidence that IGRA may have limited
sensitivity and therefore the TST is still advocated bymost experts
(11–14). In addition, indeterminate IGRA results—due to either
high interferon-γ background concentration in the negative
Abbreviations: BCG, Bacille Calmette-Guérin; CI, Confidence interval; HIV,
Human immunodeficiency virus; IGRA, Interferon-gamma release assay; IFN-γ,
Interferon-gamma; ns, not specified; QFT, QuantiFERON-TB; TB, Tuberculosis;
TST, Tuberculin skin test. ∗QFT used representative for the two reported
generations of QFT [QFT Gold and QFT-GIT (Gold In-Tube)].
control or low interferon-γ response in the positive control—
have been shown to be more frequent in children compared to
adults (15–18).
Underlying reasons for higher proportions of indeterminate
IGRA results in children are largely speculative, but several
contributing factors including age, concomitant infections and
malnutrition have been postulated (18–20).
The aim of this study was to summarize the existing data




A systematic literature search of studies reporting IGRA results
in children was performed using PubMed, Embase, and Web
of Science. Studies published until October 1st, 2018 were
considered. The study was done according to the preferred
reporting items for systematic reviews and meta-analyses
(PRISMA) statement (21) (Supplementary Material 1 PRISMA
Checklist). The following search terms were used: (tuberculosis
OR TB) AND [(((t-spot.tb) OR t-spot) OR quantiferon-tb) OR
quantiferon] AND (children OR pediatric OR pediatric). The
following inclusion criteria were used (i) patients in the pediatric
age range with a mean or median age <18 years and a maximum
upper age range of 24 years, (ii) results of at least one of the
commercially available IGRA detailed (including a statement
about indeterminate test results), (iii) publication in English,
French, or German. Case reports, case series, conference abstracts
and studies involving fewer than 10 participants, commentaries
and reviews were excluded. The search and selection of included
studies was done by MG, NM, and NR. In unclear cases a joint
decision for inclusion or exclusion of the study was made.
Data Extraction
Data were extracted using a standard form including the
following variables: year of publication, country in which the
study was done, number of participants, mean or median
age of participants, age range of participants, type of test
performed, number of positive, negative and indeterminate
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results, definition of indeterminate result, Bacillus Calmette-
Guérin (BCG) vaccination status, human immunodeficiency
virus (HIV) infection status and information on other potential
immunocompromising conditions (e.g., rheumatic diseases,
cancer) and concomitant infections (e.g., helminth or other
parasitic infections).
Statistical Analysis
The primary outcome was the proportion of indeterminate IGRA
results, which was calculated as the number of indeterminate test
results divided by the total number of valid test results. Stratified
meta-analyses for proportions were performed using a random
effects model and the DerSimonian and Laird method, with
the estimate of heterogeneity taken from the inverse-variance
fixed-effect model. Stratification variables comprised type of
IGRA used (QuantiFERON-TB and T-SPOT.TB), age groups
(0–7 ≥ 8 years), geographical location of the population under
study (Africa, Australia, North America, South America, Asia,
Europe) and immune status (HIV infection rate groups, and
presence of other immunocompromising factors). Heterogeneity
was determined using the I2 statistic.
In studies comparing both QuantiFERON-TB and T-
SPOT.TB, additional stratified meta-analyses for risk
differences were performed. Risk differences were defined
as the difference in the proportion of indeterminate results
between the two IGRA tests and were calculated according
to Newcombe and Altman (22). For comparison of pooled
risk difference, we applied the DerSimonian and Laird risk
difference method. Study weight was indicated by using
random effect models for the individual studies to account
for the different study characteristics. For risk difference
analysis stratification for age groups were done in two
groups (0–7 ≥ 8 years) because of the limited number of
available datasets.
To further explore potential sources of heterogeneity,
we used meta-regression if I2 was higher than 30%.
We considered the following variables as potentially
explanatory in a multivariable model: type of IGRA used,
age group, geographic location of the population under
study, immune status (HIV or other immunocompromising
conditions) were considered as explanatory variables in a
multivariable model.
We used GraphPad Prism Version 7.02 (GraphPad Software,
San Diego, CA, USA) and Stata Version 15.1 (StataCorp, College
Station, TX, USA) to generate figures and performmeta-analyses.
We reported estimated effect sizes with corresponding 95%
confidence intervals (95% CI). A p < 0.05 was considered
statistically significant.
FIGURE 1 | Flow chart outlining selection of articles included in the review.
Frontiers in Pediatrics | www.frontiersin.org 3 May 2019 | Volume 7 | Article 208








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Frontiers in Pediatrics | www.frontiersin.org 4 May 2019 | Volume 7 | Article 208



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Frontiers in Pediatrics | www.frontiersin.org 5 May 2019 | Volume 7 | Article 208

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Frontiers in Pediatrics | www.frontiersin.org 6 May 2019 | Volume 7 | Article 208






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Frontiers in Pediatrics | www.frontiersin.org 7 May 2019 | Volume 7 | Article 208







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Frontiers in Pediatrics | www.frontiersin.org 8 May 2019 | Volume 7 | Article 208
Meier et al. Indeterminate IGRA Results in Children
RESULTS
Demographical Data of the Studies
Included
A total of 1,293 citations were identified, of which 379
publications were eligible for full-text assessment and 133
(5 of which were found through additional sources) were
included in the final analysis (Figure 1). As 21 publications
included data on both QuantiFERON-TB and T-SPOT.TB and
one study included data on two different QuantiFERON-TB
tests a total of 155 datasets were generated. Table 1 provides
an overview of the studies included and summarizes their
key characteristics.
The 155 datasets included a total of 107,418 participants
with a median number of participants of 166 (range 12–43,196)
per dataset. The mean or median age was specified in 69%
(107/155) of datasets and reported to be 7.6 and 6 years,
respectively. Upper age range was 18 years in 87.2% (116/133),
19 years in 5.3% (7/133), 24 years in 2.3% (3/133), and not
specified in 5.3% (7/133) of studies. The studies were done in
45 countries with 36.8% (49/133) in Europe, 21.8% (29/133) in
Asia, 20.3% (27/133) in Africa, 11.3% (15/133) in North America,
4.5% (6/133) in Australia, 4.5% (6/133) in South America, and
0.75% (1/133) recruited children in two continents (Asia and
South America).
The BCG vaccination rates were reported in 80% (124/155) of
datasets and varied from 0 to 100% with a median of 82%. HIV
infection rates were reported in 49% (76/155) and varied from 0
to 100% with the median infection rate of 0.05%.
In 33 datasets additional information on
immunocompromising or other factors potentially influencing
IGRA results was reported: rheumatic or autoimmune diseases
in 12.3% (19/155), various forms of cancer in 4.5% (7/155),
and parasitic infections in 6.5% (10/155) of datasets. The
range of participants included with additional factors varied
from 1 to 100% with a median of 83.1% (not specified in
2 datasets).
Definition of Indeterminate Results of
Interferon-Gamma Release Assays
A definition for indeterminate results was included in
88% (117/133) of studies with definitions provided for
QuantiFERON-TB in 85.7% (108/126) and for T-SPOT.TB in
96.7% (29/30) of datasets. Of those that included a definition for
indeterminate results most datasets 49.7% (77/155) simply stated
FIGURE 2 | Continued.
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FIGURE 2 | Proportion of indeterminate results with 95% CI by type of IGRA. Studies arranged according to year of publication.
to have used the manufacturers’ definition [QuantiFERON-TB
47.6% (60/126) and T-SPOT.TB 56.7% (17/30)]. Further to this
for the definition of indeterminate results in the QuantiFERON-
TB assay three studies used their own definitions for failed nil
controls [nil tube interferon-γ concentration of > 0.7 IU/ml
(56) and > 2.0 IU/ml (63, 147), respectively]; five studies stated
presence of high background response without reporting specific
values (23, 36, 47, 70, 74).
Definition of indeterminate results for the T-SPOT.TB most
commonly referred to low mitogen and/or high nil responses
in combination with negative antigen response without stating
specific values. Some studies indicated the absolute number of
spots as cut-offs, others defined the number of spots in relation
to the nil and/or mitogen response. In four studies a nil control
of more than 10 spots was considered indeterminate, as opposed
to the manufacturer’s definition of ≥ 6 spots (92, 98, 112, 145).
Type of Interferon-Gamma Release Assays
Of the 133 studies, 77.4% (103/133) assessed QFT only, 15.8%
(21/133) assessed both QuantiFERON-TB and T-SPOT.TB, and
6.8% (9/133) assessed T-SPOT.TB only. The proportions of
indeterminate results ranged from 0 to 35% in the included
studies. The overall pooled effect size (equivalent to the pooled
proportion of indeterminate results) was 0.04 (95% CI 0.03–0.05,
I2 = 96.32%) for both IGRAs combined.
QuantiFERON-TB was used in 124 studies including 57,183
participants. The pooled proportion of indeterminate results of
QuantiFERON-TB was 0.05 (95% CI 0.04–0.06, I2 = 96.06%)
(Figure 2). T-SPOT.TB was analyzed in 30 studies including
50,235 participants. The pooled proportion of indeterminate
results of T-SPOT.TB was 0.03 (95% CI 0.02–0.05, I2 = 95.02%).
A total of 21 studies assessed QuantiFERON-TB and T-
SPOT.TB in the same study which allowed calculation of risk
differences for the proportion of indeterminate results. The
pooled proportion of indeterminate results was lower for T-
SPOT.TB compared to QuantiFERON-TB (risk difference−0.01,
95% CI −0.03 to −0.00, I2 = 87.7%), but did not reach
statistical significance (Figure 3).
Indeterminate Results According to Age
The mean or median age was specified in 108 datasets; of those
55 datasets had median or mean ages 0–7 years 52 datasets
had median or mean ages ≥8years. The pooled proportions of
indeterminate results were 0.04 (95% CI 0.03–0.06, I2 = 94.46%)
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FIGURE 3 | Risk difference (RD) with 95% CI in studies that included a head-to-head comparison of QuantiFERON-TB and T-SPOT.TB assays. Studies arranged
according to year of publication.
FIGURE 4 | Risk differences (RD) with 95% CI in studies that included a head-to-head comparison of QuantiFERON-TB and T-SPOT.TB assays stratified by age.
Studies sorted according to year of publication.
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FIGURE 5 | Risk differences (RD) with 95% CI in studies that included a head-to-head comparison of QuantiFERON-TB and T-SPOT.TB assays stratified by continent.
Studies arranged according to year of publication.
for the age group 0–7 years and 0.04 (95% CI 0.03–0.05, I2 =
95.19%) for ≥8years. For the 48 datasets in which the mean or
median age was not specified the proportions of indeterminate
results were 0.05 (95% CI 0.03–0.06, I2 = 97.35%).
Of the 21 studies comparing both QuantiFERON-TB and
T-SPOT.TB, 16 studies specified mean or median age. The
pooled risk difference (negative values indicating lower risk of
indeterminate results in the T-SPOT.TB) for 0–7 years was
−0.01 (95% CI −0.03 to −0.01, I2 = 79.6%) and for ≥8 years
−0.01 (95% CI −0.04 to −0.02, I2 = 76.7%). For studies which
did not specify mean or median age the pooled risk difference
was −0.03 (95% CI −0.10 to −0.05, I2 = 98.5%) (Figure 4).
Risk differences within age groups for both assays were not
statistically significant.
Indeterminate Results According to
Geographical Location of the Study
Population
A stratified analysis according to continents showed the following
proportions for indeterminate IGRA results: Europe 0.03 (95%
CI 0.02–0.05, I2 = 93.49%), Africa 0.07 (95% CI 0.04–0.10, I2 =
97.02%), Australia 0.08 (95% CI 0.04–0.14, I2 = 94.33%), Asia
0.03 (95% CI 0.01–0.04, I2 = 93.12%), North America 0.03 (95%
CI 0.02–0.05, I2 = 97.48%), South America 0.09 (95% CI 0.06–
0.14, I2 = 77.03%). One report with study sites in Asia and South
America was excluded from this particular analysis, as the data
could not be separated according to site of recruitment (34).
When continent of the study was included in the risk
differences analysis the proportion of indeterminate results for
T-SPOT.TB was significantly lower compared to QuantiFERON-
TB in studies performed in Africa only (p < 0.001). The pooled
risk difference for African studies was−0.022 (95% CI−0.032 to
−0.011, I2 = 15.4%). Risk differences for studies performed on all
other continents were not statistically significant (Figures 5, 6).
Indeterminate Results by Immune Status
The pooled proportion of indeterminate IGRA results
for the 0% HIV+, 0 < 51% HIV+, 51–100% HIV+,
immunocompromised/HIV− and no information were 0.03
(95% CI 0.02–0.05, I2 = 94.45%), 0.07 (95% CI 0.04–0.11,
I2 = 97.70%), 0.03 (95% CI 0.01–0.05, I2 = 73.96%), 0.12
(95% CI 0.07–0.18, I2 = 47.12%), 0.03 (95% CI 0.03–0.04,
I2 = 94.78%), respectively.
When immune status was included in the risk difference
analysis of indeterminate results the T-SPOT.TB was associated
with lower proportions of indeterminate results only in
studies that included immunocompromised, HIV-uninfected
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FIGURE 6 | Risk differences (RD) with 95% CI in studies that included a head-to-head comparison of QuantiFERON-TB and T-SPOT.TB assays stratified by
African/Non-African origin of the study. Studies arranged according to year of publication.
participants: the pooled risk difference was −0.071(95% CI
−0.133 to −0.010, I2 = 0.0%) and statistically significant
(p = 0.022). The risk differences in the remaining groups were
not statistically significant (Figure 7).
Meta-Regression of Indeterminate Results
Of the four variables in the model (type of IGRA, age
group, continent where study was performed, immune status),
only studies including non-HIV-infected immunocompromised
patients had a statistically significant contribution to the
heterogeneity in the multiple regression model (p= 0.0003).
DISCUSSION
Indeterminate IGRA results have been reported shortly after
introduction of these tests in routine clinical use. Despite this,
analysis of indeterminate IGRA results has commonly been
neglected in the literature, with those results either having
been excluded from previous systematic literature reviews or
only having been included in very limited subgroup analyses
(11, 153, 154). To our knowledge, this systematic review is the
first to comprehensively analyse the occurrence of indeterminate
IGRA results in children and adolescents. We found that 4%
of IGRA results are indeterminate, suggesting that 1 in 25 tests
will not produce a conclusive result. The main factor associated
with indeterminate results identified in this meta-analysis was
the presence of an immunocompromising condition other than
HIV infection.
In our analysis T-SPOT.TB assays were associated with
a similar risk of indeterminate results compared to various
generations of QuantiFERON-TB tests. T-SPOT.TB assays
require lymphocyte adjustment which may reduce the
risk of an indeterminate result particularly in patients
with reduced lymphocyte count, such as HIV infection or
immunocompromising conditions associated with lymphopenia.
This assumption is confirmed by results from a meta-analysis
including studies in adult HIV-infected patients showing
that low CD4 cell counts increased indeterminate rates of
QuantiFERON-TB but not of T-SPOT.TB assays (155). Our
results contrast with another earlier meta-analysis by Diel et al
that reported fewer indeterminate results for QFT-GIT (2.1%)
compared to T-SPOT.TB (3.8%) (154). The authors concluded
that the more demanding laboratory work for the T-SPOT.TB
was likely the reason for higher indeterminate rates. However,
their analysis predominately included studies in adults, did
not include random effects models, and only included studies
published until 2009.
Immunocompromising conditions, including HIV infection,
have been identified in earlier studies as a major contributing
factor to indeterminate results (16). A study by Oni et al. showed
that HIV infection in adults increased the risk of indeterminate
results, either through low positive control responses or high
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FIGURE 7 | Risk differences (RD) with 95% CI in studies that included a head-to-head comparison of QuantiFERON-TB and T-SPOT.TB assays stratified by immune
status. Studies arranged according to year of publication.
interferon-γ background concentrations in the negative control
(156). In another study by Mandalakas et al. indeterminate
results were more frequent in children infected with HIV
than in HIV-uninfected children (116). The previously reported
lower sensitivity of QuantiFERON-TB assays in HIV-infected
individuals may be linked to a higher rate of indeterminate
results, as the difference between the assays was negligible
in a study after exclusion of indeterminate results in one
analysis (157). Diel et al. reported in their meta-analysis
that the rates of indeterminate results for QuantiFERON-TB
and T-SPOT.TB assays were higher in immunocompromised
compared to immunocompetent individuals, with 6.1 and 4.4%,
respectively (154).
Further factors have been shown to influence IGRA
results, particularly chronic rheumatic or auto-inflammatory
diseases (158, 159). IGRA performance depends on
intact cellular Th1 responses. Helminth infections, which
primarily induce Th2 responses, may alter cytokine
production and thereby increase the rate of indeterminate
results (20, 150, 160, 161).
Importantly, in our analysis younger age was not associated
with indeterminate results, reflected in similar proportions of
indeterminate IGRA results in all age groups. This conflicts with
several studies that have reported a clear correlation between
IGRA performance, proportions of indeterminate results and
age (15, 16, 18, 27, 33, 158). It is well-established that young
children have a maturing immune system that may result in
diminished cytokine release (162, 163). The link between age
and cytokine concentrations has also been shown in numerous
studies in healthy children unrelated to TB diagnostics (162,
163). One potential reason for not detecting a significant
association between age and indeterminate IGRA results in
this meta-analysis is that aggregate data based on the reported
mean/median ages rather than individual patient data were used
for this analysis.
There were several factors we were unable to analyse in
the datasets that have been reported in some of the included
studies, which mainly concern pre-analytical factors. Several
studies in children and in adults found a decrease in interferon-
γ production and indeterminate IGRA results to be associated
with delayed sample incubation, shipping of samples, variation
in environmental temperatures, and poor phlebotomy technique
(164–168). In addition, co-medication may influence results
as a recent ex vivo study showed that both corticosteroids
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and anti-TNF-alpha agents can cause false-negative IGRA
results, and potentially also increase the rate of indeterminate
results (169).
One potential limitation of our meta-analysis is the
considerable heterogeneity of the included studies. Despite
using empirical random effects weighting, excluding studies with
< 10 participants, and using only data of the two commercially
available IGRAs, heterogeneity remained. Moreover, it is
possible that studies with poor IGRA performance and higher
proportion of indeterminate results were less likely to be
published, leading to publication bias. In addition, details on the
type of QuantiFERON-TB assays used were often not reported
in the publications, precluding a comparison of different
test generations.
CONCLUSIONS
In children, indeterminate IGRA results occur in 1 in 25 tests
performed on average. Overall, there was no difference in the
proportion of indeterminate results between both commercial
assays. However, the data of this meta-analysis indicate that in
patients in Africa and/or children with immunocompromising
conditions other than HIV infection the T-SPOT.TB assay
appears to produce fewer indeterminate results than the
QuantiFERON-TB assays.
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